| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701430 | Journal of Thoracic Oncology | 2017 | 27 Pages |
Abstract
This pooled data analysis confirmed the robust systemic efficacy of alectinib in ALK-positive NSCLC with a durable response rate. Alectinib also had an acceptable safety profile with a longer duration of follow-up.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
James Chih-Hsin MD, PhD, Sai-Hong Ignatius MD, PhD, Luigi MD, Shirish MD, Leena MD, PhD, Dong-Wan MD, PhD, Fabrice MD, PhD, Ramaswamy MD, Anne-Marie C. MD, PhD, Lucio MD, Herve MD, Sanjay PhD, Jin Seok MD, Eric MD, Sophie MSc, Walter PhD, Bogdana MD,